NVO241227C77000
- 0.00
- 0.000.00%
Novo-Nordisk A/S Newsroom
FDA Approves First Generic of Novo Nordisk's Victoza
Novo-Nordisk A/S Options Spot-On: On December 23rd, 100.63K Contracts Were Traded, With 599.3K Open Interest
On December 23rd ET, $Novo-Nordisk A/S(NVO.US)$ had active options trading, with a total trading volume of 100.63K options for the day, of which put options accounted for 46.05% of the total
Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?
European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
BMO Capital has lowered the Target Price for Novo-Nordisk A/S to $105.
Gelonghui December 23 | BMO Capital: Downgraded the Target Price of Novo-Nordisk A/S from $156 to $105, maintaining an 'outperform market' rating. (Gelonghui)
Major Bank Rating | TD Cowen: Downgraded Novo-Nordisk A/S Target Price to $105, maintaining "Buy" rating.
On December 23, Glory Holdings reported that TD Cowen has lowered the Target Price for Novo-Nordisk A/S from $155 to $105, maintaining a Buy rating. TD Cowen pointed out that despite the trial results of CagriSema being below expectations, Novo-Nordisk A/S has a strong market position due to its main drugs, the potential of the new CagriSema trials, and a vibrant product line. (Glory Holdings)
BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105
Novo Nordisk Analyst Ratings
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
Stocks Mostly Down Pre-Bell Ahead of Holiday-Shortened Trading Week; Asia, Europe Up
AlphaValue/Baader Europe: Novo Nordisk's New Obesity Drug Holds Promise Despite Disappointing Late-Stage Data
Gerresheimer Revenue Unlikely to Be Impacted by Novo Nordisk's CagriSema Data -- Market Talk
Novo Nordisk's 27% Drop Was Market Overreaction, Analysts Say
US Stock Gold Mining | AI applications are accelerating penetration! Palantir surged over 8% last Friday; positive news from new drug trials led Teva Pharmaceutical Industries to accumulate a rise of over 33% last week, and its stock price has doubled wit
Performance and guidance exceeded expectations, with multiple Analysts raising their Target Price! Darden Restaurants, the parent company of Olive Garden, rose over 2% on the previous Trading day, accumulating a gain of more than 12% last week. The Market Cap is firmly above 20 billion USD, and the stock price has reached a new high for the year!
Honda, Nissan, Qualcomm, Eli Lilly, Tesla, Rumble, and More Stock Market Movers
Novo Nordisk's Obesity Bubble Has Burst, Intron Health Says -- Market Talk
Express News | Novo-Nordisk A/S's European stock price opened up 6%, making a strong rebound after yesterday's sharp decline.
Express News | TD COWEN: Downgraded the Target Price of Novo-Nordisk A/S from $155 to $105.
Express News | Novo Nordisk : TD Cowen Cuts Target Price to $105 From $155